- Foreign institutions collectively lowered the target prices for Budweiser Brewing Company APAC Limited and other stocks on September 29, 2026, reflecting structural pressures in the Hong Kong stock consumer sector.
- Multiple companies reported divergent performances, such as VTech Holdings experiencing a 6.88% revenue decline in FY2026 and China Taiping seeing a 19.1% contraction in first-half net profit.
- Conversely, Digital Hollywood surged 181.2% in H1 revenue after entering the Hong Kong Stock Connect, highlighting distinct differentiation among small and mid-cap stocks.
- CMBI maintained a buy rating on Fujian Haixi New Drug Industry Co., Ltd. H shares with a target price of 280.00 HKD.
- The company's stock closed at 192.70 HKD in the previous trading session.
- The analyst consensus for the stock is a strong buy with a target price consensus of 296.34 HKD.